Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.
Regorafenib has improved the survival of patients with refractory metastatic colorectal cancer (mCRC), yet the mechanisms of inherited or acquired resistance are not well understood. A total of 50 patients with refractory mCRC were enrolled. CTC enumeration was performed at baseline, day 21 after initiation of regorafenib, and at the time of progression of disease (PD) using the CellSearch System. Poly (A) mRNA was extracted from CTCs, and gene expression of epithelial and EMT markers was analyzed by a multiplex-PCR based DNA Chip. Patients with <3 CTCs at baseline and day 21 had a longer PFS than those with ≥3 CTCs (3.3 v. 2.0 months, P = 0.008 and 3.3 v. 2.0 months, P = 0.004, respectively). Patients with <3 CTCs at baseline and day 21 had a longer OS than those with ≥3 CTCs (10.0 v. 4.6 months, P < 0.001 and 8.7 v. 3.8 months, P = 0.003, respectively). In multivariable analysis, CTC counts remained significantly associated with OS at baseline and Day 21 (P = 0.019 and P = 0.028). CTC EGFR gene expression was up-regulated at day 21 and/or PD in 64% of patients. Patients had significantly increased EGFR expression at PD compared to baseline (P = 0.041) and at day 21 and/or PD compared to baseline (P = 0.004). Our findings suggest that CTC count and EGFR expression may be useful markers of regorafenib efficacy and outcomes. Upregulation of CTC EGFR expression may be a molecular escape mechanism under regorafenib therapy.